Personalis Income After Taxes 2018-2024 | PSNL

Personalis income after taxes from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Personalis Annual Income After Taxes
(Millions of US $)
2023 $-108
2022 $-113
2021 $-65
2020 $-41
2019 $-25
2018 $-20
2017 $-24
Personalis Quarterly Income After Taxes
(Millions of US $)
2024-06-30 $-13
2024-03-31 $-13
2023-12-31 $-27
2023-09-30 $-29
2023-06-30 $-24
2023-03-31 $-29
2022-12-31 $-31
2022-09-30 $-26
2022-06-30 $-28
2022-03-31 $-28
2021-12-31 $-20
2021-09-30 $-18
2021-06-30 $-15
2021-03-31 $-12
2020-12-31 $-13
2020-09-30 $-10
2020-06-30 $-9
2020-03-31 $-9
2019-12-31 $-7
2019-09-30 $-7
2019-06-30 $-6
2019-03-31 $-6
2018-12-31
2018-09-30 $-4
2018-06-30 $-7
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.278B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00